REPL News and Press, Replimune Group Inc. From 11/26/25

2025-11-26 15:13:03 ET More on Markets The 'Real' Economy Is In Real Trouble Boomer Blues, Not Gen Z? SPYI Vs. SPY: The Case For Covered Calls In Two Charts Mixed signals as S&P 500’s December strength weakens in recent decade Sociét&#...

2025-11-24 12:56:15 ET Read the full article on Seeking Alpha For further details see: Iovance Biotherapeutics: Several Positives, But Competition Still Threatens

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus niv...

2025-11-06 08:26:20 ET More on Replimune Group Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating Replimune soars 108% on BLA resubmission acceptance of melanoma asset ...

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a busi...

2025-11-03 04:15:14 ET BMO Capital analyst issues MARKET PERFORM recommendation for REPL on November 3, 2025 05:04AM ET. The previous analyst recommendation was Outperform. REPL was trading at $9.73 at issue of the analyst recommendation. The overall analyst consensus : ...

2025-10-27 08:15:14 ET H.C. Wainwright analyst issues BUY recommendation for REPL on October 27, 2025 10:17AM ET. The previous analyst recommendation was Buy. REPL was trading at $8.8 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2025-10-21 07:30:16 ET Replimune Overview Replimune ( REPL ) has been on quite the ride since my latest Sell rating in July 2025.... Read the full article on Seeking Alpha For further details see: Replimune: Acceptance Confirms Completeness, Not Approval (Rat...

A look at the top 10 most actives in the United States Beyond Meat Inc. (BYND) rose 127.7% to $1.47 on volume of 1,117,806,955 shares AiRWA Inc. (YYAI) fell 17.3% to $0.1001 on volume of 366,562,519 shares Adaptimmune Therapeutics plc (ADAP) fell 70.5% to $0.059 on volume of 318,840,954 sha...

2025-10-20 12:41:14 ET DENVER, Colo., Oct 20, 2025 ( 247marketnews.com )- Wall Street is dialing into a mix of bold biotech breakthroughs, AI-powered real estate finance, and a Live Music Innovator that could redraw the sentertainment map. Here’s what’s driving the action ...